An investigational new drug treatment program for patients with gemcitabine: Results for over 3000 patients with pancreatic carcinoma

Cancer

Volumn 85, Issue 6, 1999, Pages 1261-1268

  Storniolo, Anna Maria ^a   Enas, Nathan H ^a   Brown, Cheryl A ^a   Voi, Maurizio ^a   Rothenberg, Mace L ^b   Schilsky, Richard ^c  

^a ELI LILLY AND COMPANY   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

Author keywords

Clinical benefit; Diseaserelated symptom improvement; Gemcitabine; Pain; Pancreatic carcinoma; Performance status; Quality of life; Survival

Indexed keywords

GEMCITABINE;

ADULT; AGED; ARTICLE; ASTHENIA; CANCER SURVIVAL; CLINICAL TRIAL; DRUG APPROVAL; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG RESPONSE; DRUG SCREENING; FEMALE; FEVER; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; MALE; PANCREAS CARCINOMA; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0033559213     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19990315)85:6<1261::AID-CNCR7>3.0.CO;2-T     Document Type: Article

References (13)

1. Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403-13.
2. Rothenberg ML, Abbruzzese JL, Moore M, Portenoy RK, Robertson JM, Wanebo HJ. A rationale for expanding the endpoints for clinical trials in advanced pancreatic carcinoma. Cancer 1996a;78:627-32.
3. Von Hoff DD, Green MR, editors. Gemcitabine HCl: combined efficacy and tolerability in managing the solid tumor patient. Semin Oncol 1996;23(Suppl 10):1-100.
4. Casper ES, Green MR, Kelsen DP, Heelan RT, Brown TD, Flombaum CD, et al. Phase II trial of gemcitabine (2′2′-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs 1994;12:1229-34.
5. Carmichael J, Fink U, Russell RCG, Spittle MF, Harris AL, Spiessi G, et al. Phase II study of gemcitabine in patients with advanced pancreas cancer. Br J Cancer 1996;73:101-5.
6. Rothenberg ML, Moore MJ, Cripps MC, Andersen JS, Portenoy RK, Burris HA, et al. A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol 1996b;7:347-53.
7. Andersen JS, Burris HA, Casper E, Clayman M, Green M, Nelson RL, et al. Development of a new system for assessing clinical benefit for patients with advanced pancreatic cancer [abstract 1600]. Proc Am Soc Clin Oncol 1994;13:461.
8. Efron, B. Censored data and the bootstrap. J Am Stat Assoc 1981;76:312-19.
9. Leemis LM, Trivedi KS. A comparison of approximate interval estimators for the Bernoulli parameter. Am Stat 1996; 50(1):63-8.
10. Alter CL. Palliative and supportive care of patients with pancreatic cancer. Semin Oncol 1996;23:229-40.
11. Howard JM, Jordan GL Jr. Cancer of the pancreas. Curr Prob Cancer 1977;2(3):1-52.
12. O'Shaughnessy JA, Wittes RE, Burke G, Friedman MA, Johnson JR, Neiderhuber JE, et al. Commentary concerning demonstration of safety and efficacy of investigational anticancer agents in clinical trials. J Clin Oncol 1991;9:2225-32.
13. Green MR. Gemcitabine safety overview. Semin Oncol 1996; 23(5-Suppl 10):32-5.